Avantor® Reports Second Quarter 2023 Results
- CEO expresses confidence in long-term growth outlook despite challenging market trends
- Adjusted EBITDA margin in line with guidance for the quarter
- Strategic investments in portfolio, global footprint, and innovation platform to enhance shareholder value over the long term
- Net sales decreased by 8.7%
- Core organic sales declined by 6.5%
- Net income decreased to ($7.3) million from $187.4 million in the second quarter of 2022
- Net sales of
, decrease of$1.74 billion 8.7% ; core organic decline of6.5% - Net income of
( ; Adjusted EBITDA of$7.3) million $343.0 million - Diluted GAAP EPS of (
); adjusted EPS of$0.01 $0.28 - Operating cash flow of
; free cash flow of$168.2 million $138.1 million - Adjusted net leverage of 3.9X
"While market trends during the quarter, especially in biopharma, were more challenging than anticipated, we leveraged the Avantor Business System to drive productivity and control costs, enabling us to deliver adjusted EBITDA margin, earnings, and free cash flow performance in line with our guidance for the quarter," said Michael Stubblefield, President and Chief Executive Officer.
"We are confident in our platform, market position and long-term growth outlook. We continue to take action to offset current headwinds, while making strategic investments in our portfolio, global footprint and innovation platform. These efforts will enable us to meet customer needs, capitalize on growth opportunities when market trends improve and enhance shareholder value over the long term," added Stubblefield.
Second Quarter 2023
For the three months ended June 30, 2023, net sales were
Our net income was negatively impacted by a non-cash impairment expense of approximately
Diluted earnings per share on a GAAP basis was (
Operating cash flow in the quarter was
Adjusted net leverage was 3.9X as of June 30, 2023, and we repaid more than
Second Quarter 2023 – Segment Results
Management uses Adjusted EBITDA to measure and evaluate the internal operating performance of the Company's business segments. Adjusted EBITDA is also our segment reporting profitability measure under generally accepted accounting principles.
- Net sales were
, a reported decrease of$1,025.6 million 11.3% , as compared to in the second quarter of 2022. Core organic sales decreased$1,156.6 million 8.8% . - Adjusted EBITDA margin decreased approximately 95 basis points to
24.1% .
- Net sales were
, a reported decrease of$606.9 million 2.7% , as compared to in the second quarter of 2022. Core organic sales decreased$623.8 million 1.8% . - Adjusted EBITDA margin decreased approximately 80 basis points to
18.3% .
AMEA
- Net sales were
, a reported decrease of$111.4 million 14.4% , as compared to in the second quarter of 2022. Core organic sales decreased$130.1 million 8.7% . - Adjusted EBITDA margin decreased approximately 405 basis points to
23.7% .
Conference Call
We will host a conference call to discuss our results today, July 28, 2023, at 8:00 a.m. Eastern Time. The live webcast and presentation as well as a replay will be available on the investor section of Avantor's website.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com.
Use of Non-GAAP Financial Measures
To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with
The non-GAAP financial measures used in this press release are sales growth on an organic basis, sales growth on a core organic basis, Adjusted EBITDA, adjusted net income, adjusted EPS, adjusted net leverage and free cash flow.
- Sales growth on an organic basis eliminates from our reported net sales growth the impacts of earnings from any acquired or disposed businesses that have been owned for less than one year and changes in foreign currency exchange rates. Sales growth on a core organic basis eliminates from our organic growth the impacts of any COVID-19 related net sales. We believe that these measurements are useful as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented.
- Adjusted EBITDA is to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. We believe that this measurement is useful as a way to analyze the underlying trends in our business consistently across the periods presented.
- Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) net foreign currency remeasurement gains or losses relating to financing activities, (iii) losses on extinguishment of debt, (iv) charges associated with the impairment of certain assets, (v) other costs or credits that are either isolated or cannot be expected to recur with any regularity or predictability. From this amount, we then add or subtract an assumed incremental income tax impact on the above noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measurement is useful as a way to analyze the business consistently across the periods presented.
- Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measurement is an additional way to analyze the underlying trends in our business consistently across the periods presented.
- Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions as if those acquisitions had occurred on the first day of the trailing 12-month period). We believe that this measurement is a useful way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business.
- Free cash flow is equal to our cash flow from operating activities, excluding acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful as it provides a view on the Company's ability to generate cash for use in financing or investment activities.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.
Forward-Looking and Cautionary Statements
This press release contains forward-looking statements. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "believe," "estimate," "expect," "forecast," "intend," "likely," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.
Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.
All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.
Investor Relations Contact
Christina Jones
Vice President, Investor Relations
Avantor
+1 805-617-5297
Christina.Jones@avantorsciences.com
Media Contact
Emily Collins
Vice President, External Communications
Avantor
+1 332-239-3910
Emily.collins@avantorsciences.com
Avantor, Inc. and subsidiaries Unaudited condensed consolidated statements of operations | |||||||
(in millions, except per share data) | Three months ended | Six months ended | |||||
2023 | 2022 | 2023 | 2022 | ||||
Net sales | $ 1,743.9 | $ 1,910.5 | $ 3,524.2 | $ 3,860.9 | |||
Cost of sales | 1,153.9 | 1,262.8 | 2,309.4 | 2,523.3 | |||
Gross profit | 590.0 | 647.7 | 1,214.8 | 1,337.6 | |||
Selling, general and administrative expenses | 357.5 | 352.1 | 751.1 | 735.0 | |||
Impairment charges | 160.8 | — | 160.8 | — | |||
Operating income | 71.7 | 295.6 | 302.9 | 602.6 | |||
Interest expense | (73.4) | (63.9) | (147.1) | (128.7) | |||
Loss on extinguishment of debt | (1.6) | (6.1) | (3.9) | (7.9) | |||
Other income, net | 2.0 | 0.7 | 2.6 | 2.1 | |||
(Loss) income before income taxes | (1.3) | 226.3 | 154.5 | 468.1 | |||
Income tax expense | (6.0) | (38.9) | (40.3) | (90.3) | |||
Net (loss) income | (7.3) | 187.4 | 114.2 | 377.8 | |||
Accumulation of yield on preferred stock | — | (8.1) | — | (24.2) | |||
Net (loss) income available to common stockholders | $ (7.3) | $ 179.3 | $ 114.2 | $ 353.6 | |||
(Loss) earnings per share: | |||||||
Basic | $ (0.01) | $ 0.28 | $ 0.17 | $ 0.56 | |||
Diluted | $ (0.01) | $ 0.28 | $ 0.17 | $ 0.55 | |||
Weighted average shares outstanding: | |||||||
Basic | 675.3 | 644.2 | 675.0 | 627.2 | |||
Diluted | 675.3 | 680.2 | 677.9 | 680.8 |
Avantor, Inc. and subsidiaries Unaudited condensed consolidated balance sheets | |||
(in millions) | June 30, 2023 | December 31, 2022 | |
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 236.4 | $ 372.9 | |
Accounts receivable, net | 1,216.0 | 1,218.4 | |
Inventory | 890.4 | 913.5 | |
Other current assets | 156.3 | 153.1 | |
Total current assets | 2,499.1 | 2,657.9 | |
Property, plant and equipment, net | 698.2 | 727.0 | |
Other intangible assets, net | 3,895.4 | 4,133.3 | |
Goodwill | 5,693.9 | 5,652.6 | |
Other assets | 276.7 | 293.5 | |
Total assets | $ 13,063.3 | $ 13,464.3 | |
Liabilities and stockholders' equity | |||
Current liabilities: | |||
Current portion of debt | $ 314.0 | $ 364.2 | |
Accounts payable | 686.6 | 758.2 | |
Employee-related liabilities | 124.3 | 122.4 | |
Accrued interest | 49.3 | 49.9 | |
Other current liabilities | 375.9 | 364.1 | |
Total current liabilities | 1,550.1 | 1,658.8 | |
Debt, net of current portion | 5,570.3 | 5,923.3 | |
Deferred income tax liabilities | 662.8 | 731.4 | |
Other liabilities | 268.8 | 295.4 | |
Total liabilities | 8,052.0 | 8,608.9 | |
Stockholders' equity: | |||
Common stock including paid-in capital | 3,798.6 | 3,785.3 | |
Accumulated earnings | 1,284.6 | 1,170.4 | |
Accumulated other comprehensive loss | (71.9) | (100.3) | |
Total stockholders' equity | 5,011.3 | 4,855.4 | |
Total liabilities and stockholders' equity | $ 13,063.3 | $ 13,464.3 |
Avantor, Inc. and subsidiaries Unaudited condensed consolidated statements of cash flows | |||||||
(in millions) | Three months ended | Six months ended | |||||
2023 | 2022 | 2023 | 2022 | ||||
Cash flows from operating activities: | |||||||
Net (loss) income | $ (7.3) | $ 187.4 | $ 114.2 | $ 377.8 | |||
Reconciling adjustments: | |||||||
Depreciation and amortization | 102.6 | 89.7 | 203.7 | 204.2 | |||
Impairment charges | 160.8 | — | 160.8 | — | |||
Stock-based compensation expense | 9.2 | 13.0 | 21.9 | 23.7 | |||
Provision for accounts receivable and | 30.6 | 12.3 | 43.1 | 28.2 | |||
Deferred income tax benefit | (38.3) | (17.2) | (64.7) | (39.5) | |||
Amortization of deferred financing costs | 3.3 | 4.1 | 6.7 | 8.5 | |||
Loss on extinguishment of debt | 1.6 | 6.1 | 3.9 | 7.9 | |||
Foreign currency remeasurement (gain) loss | (1.9) | 1.2 | (0.1) | (0.6) | |||
Changes in assets and liabilities: | |||||||
Accounts receivable | 60.1 | 39.1 | 7.9 | (98.2) | |||
Inventory | (8.8) | (46.7) | (1.7) | (93.1) | |||
Accounts payable | (75.0) | (0.8) | (74.4) | 72.4 | |||
Accrued interest | 9.9 | 9.1 | (0.6) | (0.9) | |||
Other assets and liabilities | (78.4) | (69.2) | (34.3) | (115.4) | |||
Other, net | (0.2) | (0.6) | 1.3 | 4.7 | |||
Net cash provided by operating activities | 168.2 | 227.5 | 387.7 | 379.7 | |||
Cash flows from investing activities: | |||||||
Capital expenditures | (30.1) | (36.3) | (58.1) | (60.8) | |||
Cash paid for acquisitions, net of cash acquired | — | (4.9) | — | (20.2) | |||
Other | 0.7 | 0.1 | 1.4 | 0.4 | |||
Net cash used in investing activities | (29.4) | (41.1) | (56.7) | (80.6) | |||
Cash flows from financing activities: | |||||||
Debt borrowings | — | 210.0 | — | 210.0 | |||
Debt repayments | (190.8) | (412.0) | (460.3) | (523.9) | |||
Payments of debt refinancing fees and premiums | (2.3) | — | (2.3) | — | |||
Payments of dividends on preferred stock | — | (16.3) | — | (32.4) | |||
Proceeds received from exercise of stock options | 2.1 | 5.9 | 4.7 | 11.6 | |||
Shares repurchased to satisfy employee tax | (5.2) | (8.1) | (13.3) | (13.0) | |||
Net cash used in financing activities | (196.2) | (220.5) | (471.2) | (347.7) | |||
Effect of currency rate changes on cash | (0.7) | (13.3) | 4.1 | (17.5) | |||
Net change in cash, cash equivalents and restricted | (58.1) | (47.4) | (136.1) | (66.1) | |||
Cash, cash equivalents and restricted cash, beginning | 318.9 | 308.4 | 396.9 | 327.1 | |||
Cash, cash equivalents and restricted cash, end of | $ 260.8 | $ 261.0 | $ 260.8 | $ 261.0 |
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures | |||||||
(in millions) | Three months ended | Six months ended | |||||
2023 | 2022 | 2023 | 2022 | ||||
Net (loss) income | $ (7.3) | $ 187.4 | $ 114.2 | $ 377.8 | |||
Amortization | 78.9 | 67.8 | 157.3 | 160.0 | |||
Loss on extinguishment of debt | 1.6 | 6.1 | 3.9 | 7.9 | |||
Net foreign currency (gain) loss from financing | (1.6) | 0.9 | (1.8) | 1.0 | |||
Other stock-based compensation benefit | (0.1) | (0.4) | — | (1.7) | |||
Integration-related expenses1 | (0.6) | 3.3 | 8.1 | 7.2 | |||
Purchase accounting adjustments2 | — | 13.8 | — | 9.4 | |||
Restructuring and severance charges3 | 7.2 | 0.5 | 11.9 | 2.4 | |||
Reserve for certain legal matters | 1.0 | — | 1.0 | — | |||
Impairment charges4 | 160.8 | — | 160.8 | — | |||
Income tax benefit applicable to pretax adjustments | (53.5) | (27.9) | (73.6) | (53.7) | |||
Adjusted net income | 186.4 | 251.5 | 381.8 | 510.3 | |||
Interest expense | 73.4 | 63.9 | 147.1 | 128.7 | |||
Depreciation | 23.7 | 21.9 | 46.4 | 44.2 | |||
Income tax provision applicable to Adjusted Net income | 59.5 | 66.8 | 113.9 | 144.0 | |||
Adjusted EBITDA | $ 343.0 | $ 404.1 | $ 689.2 | $ 827.2 |
━━━━━━━━━
1. | Represents non-recurring direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition. |
2. | Represents the non-cash reduction of contingent consideration related to the Ritter acquisition and the amortization of the purchase accounting adjustment to record inventory acquired from Masterflex at fair value. |
3. | Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs. |
4. | Related to impairment of Ritter asset group. |
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures (continued)
Earnings per share | |||||||
(shares in millions) | Three months ended June 30, | Six months ended June 30, | |||||
2023 | 2022 | 2023 | 2022 | ||||
Diluted (loss) earnings per share (GAAP) | $ (0.01) | $ 0.28 | $ 0.17 | $ 0.55 | |||
Dilutive impact of convertible instruments | — | — | — | — | |||
Fully diluted (loss) earnings per share (non- | (0.01) | 0.28 | 0.17 | 0.55 | |||
Amortization | 0.12 | 0.10 | 0.23 | 0.24 | |||
Loss on extinguishment of debt | — | 0.01 | 0.01 | 0.01 | |||
Net foreign currency (gain) loss from financing | — | — | — | — | |||
Other stock-based compensation benefit | — | — | — | — | |||
Integration-related expenses | — | — | 0.01 | 0.01 | |||
Purchase accounting adjustments | — | 0.02 | — | 0.01 | |||
Restructuring and severance charges | 0.01 | — | 0.02 | 0.01 | |||
Reserve for certain legal matters | — | — | — | — | |||
Impairment charges | 0.24 | — | 0.24 | — | |||
Income tax benefit applicable to pretax adjustments | (0.08) | (0.04) | (0.12) | (0.08) | |||
Adjusted EPS (non-GAAP) | $ 0.28 | $ 0.37 | $ 0.56 | $ 0.75 | |||
Weighted average shares outstanding: | |||||||
Diluted (GAAP) | 675.3 | 680.2 | 677.9 | 680.8 | |||
Incremental shares excluded for GAAP | 2.4 | — | — | — | |||
Share count for Adjusted EPS (non-GAAP) | 677.7 | 680.2 | 677.9 | 680.8 |
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures (continued)
Free cash flow | |||||||||||
(in millions) | Three months ended June 30, | Six months ended June 30, | |||||||||
2023 | 2022 | 2023 | 2022 | ||||||||
Net cash provided by operating activities | $ 168.2 | $ 227.5 | $ 387.7 | $ 379.7 | |||||||
Capital expenditures | (30.1) | (36.3) | (58.1) | (60.8) | |||||||
Free cash flow (non-GAAP) | $ 138.1 | $ 191.2 | $ 329.6 | $ 318.9 | |||||||
Adjusted net leverage | |||||||||||
(dollars in millions) | June 30, 2023 | ||||||||||
Total debt, gross | $ 5,936.2 | ||||||||||
Less cash and cash equivalents | (236.4) | ||||||||||
$ 5,699.8 | |||||||||||
Trailing twelve months Adjusted EBITDA | $ 1,432.7 | ||||||||||
Trailing twelve months ongoing stock-based compensation expense | 45.6 | ||||||||||
$ 1,478.3 | |||||||||||
Adjusted net leverage (non-GAAP) | 3.9 x |
Avantor, Inc. and subsidiaries Reconciliations of non-GAAP measures (continued)
Net sales | |||||||||||||
(in millions) | June 30, | Reconciliation of reported change to organic and core organic change | |||||||||||
Reported change | Foreign currency impact | Organic | COVID -19 | Core organic1 | |||||||||
2023 | 2022 | ||||||||||||
Three months ended: | |||||||||||||
$ 1,025.6 | $ (131.0) | $ (1.2) | $ (129.8) | $ (28.3) | $ (101.5) | ||||||||
606.9 | 623.8 | (16.9) | 11.1 | (28.0) | (16.8) | (11.2) | |||||||
AMEA | 111.4 | 130.1 | (18.7) | (2.4) | (16.3) | (5.1) | (11.2) | ||||||
Total | $ 1,743.9 | $ (166.6) | $ 7.5 | $ (174.1) | $ (50.2) | $ (123.9) | |||||||
Six months ended: | |||||||||||||
$ 2,057.6 | $ (242.4) | $ (4.7) | $ (237.7) | $ (93.5) | $ (144.2) | ||||||||
1,237.1 | 1,304.2 | (67.1) | (21.7) | (45.4) | (40.8) | (4.6) | |||||||
AMEA | 229.5 | 256.7 | (27.2) | (8.0) | (19.2) | (9.3) | (9.9) | ||||||
Total | $ 3,524.2 | $ (336.7) | $ (34.4) | $ (302.3) | $ (143.6) | $ (158.7) |
_______________ | |
1. | Core organic sales growth eliminates from our organic growth the impact from the change in sales of COVID-19 related offerings from 2022 to 2023. Numbers in this column are calculated by removing the impact of COVID-19 sales from the numbers in the "Organic" column. |
Adjusted EBITDA | |||||||
(in millions) | Three months ended | Six months ended | |||||
2023 | 2022 | 2023 | 2022 | ||||
$ 247.2 | $ 289.8 | $ 487.6 | $ 584.0 | ||||
111.2 | 119.3 | 232.9 | 262.7 | ||||
AMEA | 26.4 | 36.1 | 59.9 | 65.4 | |||
Corporate | (41.8) | (41.1) | (91.2) | (84.9) | |||
Total | $ 343.0 | $ 404.1 | $ 689.2 | $ 827.2 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-reports-second-quarter-2023-results-301887874.html
SOURCE Avantor and Financial News
FAQ
What were Avantor's net sales in Q2 2023?
What was Avantor's adjusted EBITDA in Q2 2023?
What was Avantor's net income in Q2 2023?